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ABSTRACT
Streptococcus pneumoniae serotype 1 is one of the leading causes of invasive
pneumococcal disease. However, this invasive serotype is hardly found in nasopha-
ryngeal asymptomatic carriage and therefore large epidemiological studies are
needed to assess the dynamics of serotype 1 infection. Within the context of a large
cluster randomized trial conducted in rural Gambia to assess the impact of PCV-7
vaccination on nasopharyngeal carriage, we present an ancillary analysis describing
the prevalence of nasopharyngeal carriage of pneumococcal serotype 1 and temporal
changes of its more frequent genotypes. Nasopharyngeal swabs (NPS) were collected
before PCV-7 vaccination (December 2003–May 2004) and up to 30 months after
PCV-7 vaccination. The post-vaccination time was divided in three periods to
ensure an equal distribution of the number of samples: (1) July 2006–March 2007,
(2) April 2007–March 2008 and (3) April 2008–Feb 2009. S. pneumoniae serotype
1 were genotyped by MLST. Serotype 1 was recovered from 87 (0.71%) of 12,319
NPS samples collected. In the pre-vaccination period, prevalence of serotype 1 was
0.47% in both study arms. In the post-vaccination periods, prevalence in the fully
vaccinated villages ranged between 0.08% in period 1 and 0.165% in period 2, while
prevalence in partly vaccinated villages was between 0.17% in period 3 and 1.34%
in period 2. Overall, four different genotypes were obtained, with ST3081 the most
prevalent (60.71%), followed by ST618 (29.76%). ST3081 was found only in post-
vaccination period 2 and 3, while ST618 had disappeared in post-vaccination period
3. Distribution of these major genotypes was similar in both study arms. Emergence
of ST3081 and concomitant disappearance of ST618 may suggest a change in the
molecular epidemiology of pneumococcal serotype 1 in this region. This change
is not likely to be associated with the introduction of PCV-7 which lacks serotype
1, as it was observed simultaneously in both study arms. Future population-based
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epidemiological studies will provide further evidence of substantive changes in the
pneumococcal serotype 1 epidemiology and the likely mechanisms.
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INTRODUCTION
Streptococcus pneumoniae is usually found in the nasopharynx of healthy individuals,
which is considered a necessary step preceding invasive pneumococcal disease (IPD),
including pneumonia, meningitis, and bacteraemia (Gleich et al., 2000; Bogaert, De Groot
& Hermans, 2004; Baker et al., 2005; Adegbola et al., 2006; Hill et al., 2006; Ahern & Raszka,
2009; Balicer et al., 2010). There are over 90 different S. pneumoniae serotypes of which
serotype 1 is a common cause of IPD worldwide, with particular high rates of disease in
sub-Saharan Africa (Hausdorff et al., 2000; Adegbola et al., 2006; Gessner, Mueller & Yaro,
2010).
As cases of invasive disease represent only a small fraction of the pneumococcal
burden, there is an increasing interest on evaluating the prevalence of pneumococcal
asymptomatic carriage in the nasopharynx, since this is important in understanding the
dynamics of disease and transmission as well as providing a basis for assessing the impact
of interventions (Bogaert, De Groot & Hermans, 2004). Interestingly, serotype 1 is rarely
found in the nasopharynx of healthy individuals with prevalence always below 1%–2%
(Hill et al., 2006; Laval et al., 2006; Antonio et al., 2008; Nunes et al., 2008). As a result, there
are just few studies evaluating the dynamics of serotype 1 in nasopharyngeal carriage as
large epidemiological studies are needed.
Although PCV-7, the first licensed pneumococcal vaccine, did not include serotype 1 in
its formulation, new PCV licensed vaccines (PCV-10 and PCV-13) include this serotype
and therefore understanding the dynamics of serotype 1 carriage has become a priority.
Within the context of a cluster-randomized trial conducted in rural Gambia (Roca et al.,
2011), we collected a large number of NPS (12, 319 samples) before and up to 30 months
after starting the trial (Hill et al., 2006; Roca et al., 2011). As an ancillary study of the trial,
we describe the dynamics of pneumococcal serotype 1 nasopharyngeal carriage within a
period of 6 years before and after the PCV-7 trial.
MATERIALS AND METHODS
Study design and collection of isolates
This study was an ancillary study of large pneumococcal carriage studies conducted in 21
selected villages in rural Gambia as previously described (Hill et al., 2006; Roca et al., 2011).
Firstly, a pre-vaccination cross sectional survey was conducted between December 2003
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Table 1 Prevalence of nasopharyngeal pneumococcal serotype 1 carriage between pre-vaccination study period and each of the post-vaccination
study periods in The Gambia.
Study period Number of NPS Number of serotype 1 isolates (%) P value
Pre-vaccination period (December 2003–May 2004) 2,746 13 (0.47) <0.001
Post vaccination Period 1 (July 2006–March 2007) 3,986 9 (0.23)
Post vaccination Period 2 (April 2007–March 2008) 3,469 52 (1.50)
Post vaccination Period 3 (April 2008–Feb 2009) 2,118 13 (0.61)
Total 12,319 87 (0.71)
and May 2004 in which NP samples were collected from subjects of all age groups (Hill et
al., 2006). Following this, a single-blind, cluster-randomized (by village) trial to evaluate
the impact of PCV-7 on pneumococcal carriage was conducted in the study villages
(Roca et al., 2011). In one group of 11 villages, all individuals over the age of 30 months
received one dose of PCV-7, whilst subjects in this age group resident in 10 control villages
received one dose of serogroup C meningococcal conjugate vaccine. All children less than
30 months of age in both study groups and infants born during the course of the trial
received PCV-7. The trial showed a marked decrease of nasopharyngeal carriage of vaccine
type (VT) pneumococci in all age groups and both study arms, with a more marked drop
in villages where the whole community had received PCV-7 (Roca et al., 2011). There
was little change in the overall prevalence of NVT carriage following introduction of the
vaccine (Roca et al., 2011).
NP swabs were collected as part of several ongoing studies. First, a large pre-vaccination
cross-sectional survey (CSS) conducted in 2003–2004, prior to a PCV-7 randomized
trial (Hill et al., 2006). Later, as part of the cluster-randomized PCV-7 trial, NPS were
collected in three different cross-sectional surveys (from 4–6 months, 12–14 months and
up to 30 months) (Roca et al., 2011) and as well as a longitudinal study between 4 and 30
months (unpublished data) after vaccination (Table 1). For the purposes of this analysis,
post-vaccination data were shown stratified in three different time-periods defined to
ensure at least 2,000 samples in each period as the number of samples were not equally
distributed throughout the follow up period (Table 1).
Approval for this study was obtained from the Joint Medical Research Council
(MRC)/Gambia Government Ethics Committee and the Ethics Committee of the London
School of Hygiene & Tropical Medicine, UK (SCC number 1032, ISRCTN 51695599).
Community and individual consent was obtained from study participants and the conduct
of the trial was guided by a Data Safety and Monitoring Board.
Serotyping and multilocus sequence typing (MLST)
A total of 87 S. pneumoniae serotype 1 isolates obtained from NP swabs during a survey
were identified by latex agglutination (Hill et al., 2006) and confirmed by molecular
serotyping (Morais et al., 2007). Multilocus sequence typing was performed on viable S.
pneumoniae serotype 1 isolates recovered after storage at−70 ◦C as previously described
(Antonio et al., 2008).
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Data analysis
All statistical analysis were carried out in STATA (version 11; StataCorp, College Station,
Texas, USA) using Chi-square tests. p-Values less than 0.05 were taken to indicate statistical
significance. Wet season was considered from June to October each year. Sequences were
edited and aligned using the Laser Gene DNA star 7.1 software. Sequence type (ST) was
obtained by submission of sequences onto the MLST database website.
RESULTS
A total of 12,319 NP samples were collected during the study: 22.2% of which were from
the pre-vaccination period and 32.4%, 28.2% and 17.2% from the post-vaccination study
periods 1–3, respectively. The median age of sampled individuals was 15 years (IQR
5.9—45 years), 11 years (IQR 4.7—29 years), 11 years (IQR 5.6—27 years) and 14 years
(IQR 6.7—33 years), in the pre-vaccination and post vaccination periods 1–3 respectively.
The overall prevalence of S. pneumoniae in the pre-vaccination period was 71.78% (1,971
out of 2,746 samples). The overall prevalence of S. pneumoniae in the post-vaccination
periods 1–3 was 47.08% (4,507 out of 9,573 samples).
The overall prevalence of S. pneumoniae serotype 1 was 0.71% (87 of 12,319 samples
collected). Prevalence of serotype 1 carriage was highest (1.02%) among children aged
5–14 years (p < 0.001) compared to other age groups. Serotype 1 carriage prevalence
was highest in post-vaccination period 2 (1.50%) compared to the other study periods
(p< 0.001) (Table 1).
Serotype 1 isolates were likely to be found during the wet season 0.81% (40 out of 4,909
samples collected) compared to the dry season 0.64% (47 out of 7,323 samples collected)
(p= 0.268) but these were not statistically significant.
The overall prevalence of serotype 1 pneumococcal carriage was similar in vaccinated
and control villages (0.73% vs. 0.68%; p = 0.703). In the pre-vaccination study period,
prevalence of carriage of serotype 1 was the same in both vaccinated and control villages
(0.47% each). However, the prevalence was lower in vaccinated than in control villages in
post-vaccination period 1 (0.08% vs. 0.48%, p= 0.011), similar in vaccinated and control
villages in period 2 (1.65% vs. 1.34%, p= 0.459) and higher in vaccinated villages in period
3 (1.16% vs. 0.17%, p= 0.004) (Table 2).
MLST analysis was performed for 84 of the 87 serotype 1 isolates obtained (97%).
Four different STs were obtained, with ST3081 being the predominant ST (60.71%) in
both vaccinated and control villages followed by ST618 (29.76%), ST217 (7.14%) and
ST303 (2.38%). Prevalence of different STs was not associated with age groups (p= 0.368).
However, the distribution of STs differed over the course of the study (p < 0.001). ST3081
was seen only in the post vaccination periods. ST618 was seen in the pre-vaccination and
periods 1 and 2 post vaccination, but not in the post vaccination period 3 (Fig. 1). Dif-
ferences in the distribution of ST over the study periods was apparent in both vaccinated
(p = 0.002) and control (p = 0.021) villages (Fig. 2), with the observed expansion of
ST3081 and the disappearance of ST618 occurring in both groups (Figs. 1 and 2).
Ebruke et al. (2015), PeerJ, DOI 10.7717/peerj.903 4/11
Table 2 Prevalence of nasopharyngeal pneumococcal serotype 1 carriage between control and vacci-
nated villages in each study period in The Gambia.
Study period Village
group
Number of
NPS
Number of serotype
1 isolates (%)
P value
Pre-vaccination period Control 1,271 6 (0.47) 0.992
Vaccinated 1,475 7 (0.47)
Post vaccination period 1 Control 1,468 7 (0.48) 0.011
Vaccinated 2,518 2 (0.08)
Post vaccination period 2 Control 1,711 23 (1.34) 0.459
Vaccinated 1,758 29 (1.65)
Post vaccination period 3 Control 1,171 2 (0.17) 0.004
Vaccinated 947 11 (1.16)
Figure 1 Distribution of Streptococcus pneumoniae 1 genotypes across study periods in The Gambia.
DISCUSSION
Given that pneumococcal serotype 1 is one of the common cause of IPD worldwide and
the paradox of its’ rarity in nasopharyngeal carriage, it is not unsurprising that only a
few published studies have evaluated serotype 1 carriage patterns. To our knowledge, this
is the largest study evaluating the dynamics of pneumococcal serotype 1 carriage. We
present findings from as many as 87 serotype 1 isolates and report on the prevalence and
dominant genotype patterns over a 6 year period. The finding of 0.71% overall prevalence
in carriage of serotype 1 agrees with earlier findings indicating the rarity of serotype 1 in
carriage studies (Brueggemann & Spratt, 2003; Hausdorff, Feikin & Klugman, 2005; Laval
et al., 2006; Nunes et al., 2008; Smith-Vaughan et al., 2009). We also note that this low
carriage rate was observed in both the pre- and post vaccination periods with no significant
differences between study arms. However, prevalence of serotype 1 carriage was highest
in the age group 5–14 years. Findings from other studies suggest that this age group is
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Figure 2 Distribution of Streptococcus pneumoniae 1 genotypes across study periods in (a) control
and (b) vaccinated villages in The Gambia.
at particular risk for serotype 1 IPD as opposed to other serotypes (Adegbola et al., 2006;
Gessner, Mueller & Yaro, 2010).
Introduction of the pneumococcal conjugate vaccine PCV-7 is associated with a
reduction in carriage of VT serotypes but has also been linked to an increase in carriage
of NVT in some settings (Mbelle et al., 1999; Huang et al., 2005; O’Brien et al., 2007) but
not in our setting (Roca et al., 2011) and elsewhere (Millar et al., 2008; Roca et al., 2011).
In this study, serotype 1 prevalence showed variation over the study period, but this is not
likely to have been related to vaccine introduction as there was no consistent trend and no
consistent difference between vaccinated and control villages. A higher carriage rate in the
vaccinated group compared to the controls was observed in only one study period, and a
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reverse picture was observed in another post vaccination period of the study. This pattern
appears more likely to be due to natural variation over time rather than to an increase in
NVT serotypes due to community vaccination with PCV-7.
All STs obtained in this study belong to the ST217 hyper virulent clonal complex respon-
sible for several epidemic outbreaks in West Africa (Leimkugel et al., 2005; Yaro et al., 2006;
Antonio et al., 2008). The prevalence of the predominant serotype 1 genotypes (ST3081
and ST618) varied significantly over the study period. In period 3, we were unable to detect
ST618, but noted instead the predominance of its quadruple locus variant ST3081. It is
plausible that the changes between ST618 and ST3081 in this study population provide
initial evidence of an expansion of the ST217 clonal complex. However, this finding could
possibly have been due to temporal changes. On-going invasive pneumococcal disease
surveillance studies in The Gambia such as IPD surveillance in the Upper River Region
(Mackenzie et al., 2012) as well as the pneumococcal disease surveillance in the West Africa
region consortium (M Antonio, pers. comm., 2015) will provide more answers to these
questions. We have also shown, in our study area, the detection of a new sequence type
in The Gambia without evidence that this was associated with vaccination with PCV-7.
Such emergence of ST suggests natural variation in the molecular epidemiology of the
pneumococcus that requires further evaluation. A report from Brazil of a study that looked
at invasive serotype 1 isolates over 3 decades found temporal changes in pulse field gel
electrophoresis subtypes and STs over time, but the effect of pneumococcal vaccination was
not evaluated (Chiou et al., 2008). This should be closely monitored in The Gambia in the
near future, as the wider PCV formulation (PCV-13) has recently been introduced as part
of the Expanded Programme of Immunization.
However, we acknowledge some limitations with this study. Firstly, the samples in this
study were of modest size and a larger sample size would have allowed for more robust
analysis between the comparison groups. The modest number we got after sampling such
a large population goes to support the notion that serotype 1 is rare in carriage. Obtaining
a much larger sample size will therefore require very large epidemiological studies and its
attendant challenges. Secondly, this study was limited to carriage isolates from the Western
division of The Gambia. It is unclear if observations from this group are applicable to
a more heterogeneous population. There is therefore a need for further studies in The
Gambia, including population-based molecular epidemiological studies assessing the
distribution of these STs causing IPD and whole-genome comparisons in order to identify
genetic differences that could correspond with the observed differences between otherwise
highly similar strains, and such studies are currently underway (Williams et al., 2012).
CONCLUSIONS
In conclusion, in this study we show the prevalence of pneumococcal serotype 1 carriage as
well as the predominant genotypes and how they varied over the study periods, but this did
not seem related to community vaccination with PCV-7. This provides important baseline
data for further evaluation of nasopharyngeal carriage after PCV-13 has been introduced in
The Gambia.
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IPD Invasive Pneumococcal Disease
PCV-7 7 valent pneumococcal conjugate vaccine
NPS Nasopharyngeal Swab
MLST Multilocus Sequence Typing
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